- Home
- VRCA vs KZIA Comparison
VRCA vs KZIA Comparison
Compare VRCA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | KZIA |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 100.8M |
| IPO Year | 2018 | 2002 |
Fundamental Metrics
Financial Performance| Metric | VRCA | KZIA |
|---|---|---|
| Price | $6.30 | $13.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $17.00 | ★ $19.50 |
| AVG Volume (30 Days) | 70.2K | ★ 270.5K |
| Earning Date | 05-11-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $94.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.39 | $3.05 |
| 52 Week High | $9.82 | $17.40 |
Technical Indicators
Market Signals| Indicator | VRCA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 68.65 |
| Support Level | $5.16 | $5.85 |
| Resistance Level | $7.35 | $14.42 |
| Average True Range (ATR) | 0.42 | 1.18 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 46.91 | 71.84 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.